N@N

InVivo Therapeutics Receives Prestigious 2011 Apple Award for Top Publication in Breakthrough Spinal Cord Injury Research

^{Published on 2011-04-29 03:20:59 - Market Wire}
 

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that Chief Science Officer Dr. Christopher Pritchard, Ph.D., has been selected as the 2011 recipient of the American Spinal Injury Associationa™s (ASIA) prestigious Apple Award. The award recognizes excellence in publishing in spinal cord injury research across the globe.

"This award recognizes one of several landmark studies supporting our technology and our brilliant team of scientists led by our Chief Medical Officer, Dr. Eric Woodard, and M.I.T.a™s Dr. Robert S. Langer"

Dr. Pritchard and his InVivo Therapeutics team authored the article titled: aEstablishing a model spinal cord injury in the African green monkey for the preclinical evaluation of biodegradable polymer scaffolds seeded with human neural stem cells.a The article was published in 2010 in the Journal of Neuroscience Methods (188, 258-269). Co-authors are Jonathan R. Slotkin, Dou Yu, Haining Dai, Matthew S. Lawrence, Roderick T. Bronson, Francis M. Reynolds, Yang D. Teng, Eric J. Woodard, and Robert S. Langer.

aThis award recognizes one of several landmark studies supporting our technology and our brilliant team of scientists led by our Chief Medical Officer, Dr. Eric Woodard, and M.I.T.a™s Dr. Robert S. Langer,a said Frank Reynolds, CEO of InVivo Therapeutics. aAcknowledgement of this caliber is an honor and highlights the promise of our strategic initiatives. This study could not have been completed without the leadership from our Medical Director, Dr. Jonathan Slotkin, and our collaborator, Dr. Yang D. Teng, Director, Laboratories of Spinal Cord Injury and Neural Stem Cell Research at Harvard Medical School.a

InVivo Therapeutics will receive The Apple Award from David F. Apple, Jr., M.D. on June 8, 2011, during the ASIA Annual Scientific Meeting in Washington, D.C. The award consists of a check for $2,000, a commissioned and engraved crystal apple sculpture, and the invitation to keynote the 2011 Research Day at Shepherd Center.

This is the fifth year that ASIA has presented The Apple Award, named in honor of Dr. Apple, founding member and past-president of ASIA. The award is a collaboration of three entities that have been critically important to Dr. Apple during his long career in orthopaedic surgery: Shepherd Center in Atlanta, Georgia, where he served as founding medical director for 30 years; the journal Topics in Spinal Cord Injury Rehabilitation, of which Dr. Apple is editor-in-chief; and ASIA.

For more information about this press release, visit [ http://nviv.irnewsroom.com/ ] or click [ here ].

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital in Boston. For more information on InVivo Therapeutics, please visit [ www.invivotherapeutics.com ].

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Companya™s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 10-K. We do not undertake to update these forward-looking statements made by us.